Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
Jun Wang, Daniel Lam, Jeffrey Yang, Longqin Hu
Topics & Concepts
OsimertinibT790MLung cancerEpidermal growth factor receptorCancer researchTyrosine kinaseErlotinibTyrosine-kinase inhibitorChemistryEGFR inhibitorsPharmacologySmall moleculeMedicineCancerSignal transductionGefitinibOncologyInternal medicineBiochemistryLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy